{"id":2547,"date":"2025-01-23T14:50:06","date_gmt":"2025-01-23T11:50:06","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2547"},"modified":"2025-11-03T20:31:05","modified_gmt":"2025-11-03T17:31:05","slug":"fda-grants-rare-pediatric-disease-designation-to-nippon-shinyakus-exon-51-skipping-study-ns-051-ncnp-04","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/fda-grants-rare-pediatric-disease-designation-to-nippon-shinyakus-exon-51-skipping-study-ns-051-ncnp-04\/","title":{"rendered":"FDA verleiht der Exon 51 Skipping-Studie (NS-051\/NCNP-04) von Nippon Shinyaku den Status einer seltenen p\u00e4diatrischen Erkrankung"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Nippon Shinyaku und das National Center of Neurology and Psychiatry haben gemeinsam das Antisense-Oligonukleotid NS-051\/NCNP-04 entdeckt. Durch Weglassen eines Teils des genetischen Materials des Dystrophin-Gens erzeugt NS-051\/NCNP-04 ein funktionierendes Dystrophin-Protein mit einer etwas k\u00fcrzeren Kettenl\u00e4nge, das den R\u00fcckgang der Muskelfunktion verhindern soll.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mit gro\u00dfem Engagement entwickelt Nippon Shinyaku Medikamente zur Heilung seltener und hartn\u00e4ckiger Erkrankungen, um DMD-Patienten schnell L\u00f6sungen bieten zu k\u00f6nnen.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mehr lesen<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/de\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Klinische Studien zu Duchenne (Liste aller Forschungsarbeiten)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Nippon Shinyaku and the National Center of Neurology and Psychiatry jointly discovered the antisense oligonucleotide NS-051\/NCNP-04. By omitting a portion of the dystrophin gene&#8217;s genetic material, NS-051\/NCNP-04 creates a functioning dystrophin protein with a little shorter chain length, which should prevent the decline in muscle function. With a strong sense of purpose, Nippon Shinyaku has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2550,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[193,194,88,136,192],"class_list":["post-2547","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-exon-51-skipping","tag-exon-51-treatment","tag-fda","tag-nippon-shinyaku","tag-ns-051-ncnp-04"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/2547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=2547"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/2547\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/2550"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=2547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=2547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=2547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}